We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Thermo Fisher Scientific Announces SARS-CoV-2 GlobalAccess Sequencing Program

Thermo Fisher Scientific Announces SARS-CoV-2 GlobalAccess Sequencing Program content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

To accelerate national, multi-institutional efforts focused on mapping coronavirus transmission and epidemiological studies, Thermo Fisher Scientific has announced the SARS-CoV-2 GlobalAccess Sequencing Program for research consortia and industry groups battling the spread of the pandemic globally. Under the program, the company will provide 50 units of the Ion Torrent Genexus System at a subsidized price to support global collaborative COVID-19 research.

As countries begin to reopen, the need for real-time SARS-CoV-2 sequencing data that can be quickly and easily generated and shared among partners in the scientific community is critical. Access to such data can accelerate researchers’ understanding of how the virus is evolving, assist with contact tracing and transmission interruption efforts, and inform vaccine development programs. Thermo Fisher’s latest sequencing innovation is primed for what research consortia are trying to accomplish: fast, real-time, sequencing-data acquisition and sharing through a network of decentralized institutions.

The Genexus System is the world’s first turnkey next-generation sequencing (NGS) solution that is designed to deliver results in a day with five minutes of hands-on time in a decentralized laboratory setting. The platform’s ease of use and automation has been developed to provide researchers – regardless of expertise level – access to the power of NGS technology. When combined with the Ion AmpliSeq SARS-CoV-2 Research Panel, the platform provides laboratories with a powerful, specimen-to-report workflow to carry out infectious disease studies using minimal amounts of sample.

“Infectious disease researchers working to solve the SARS-CoV-2 pandemic are in need of automated, next-generation sequencing technology that is able to deliver results in real-time in order to combat the virus,” said Dr. Carl Morrison, senior vice president of Scientific Development and Integrative Medicine at Roswell Park Comprehensive Cancer Center, who will be employing the Genexus System as part of a new precision-medicine research effort, the Western New York Immunogenomic COVID-19 Study.

“As we continue to support our customers by providing millions of COVID-19 tests each week, Thermo Fisher is increasing its efforts even further to accelerate the next phase of SARS-CoV-2 research with our next generation sequencing technology,” said Peter Silvester, senior vice president and president of Life Sciences Solutions at Thermo Fisher Scientific.